MFN2 and Parkinson disease: Further study revealed that metformin targeted Mfn2 to normalize mitochondrial function to reduce mitochondrial DNA (mtDNA) release, thereby inhibiting the cGAS-STING signal activation, which contributed to delaying the astrocyte senescence and PD progression.